BTIG Downgrades Teva Pharma (TEVA) to Neutral
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BTIG downgraded Teva Pharma (NYSE: TEVA) from Buy to Neutral and removed its price target. Analyst Timothy Chiang noted Copaxone risk.
"We downgrade TEVA shares to Neutral based on three key factors: 1) poor visibility on near term revenue growth drivers for the generic / branded segments, 2) heavy debt leverage (Teva has ~$36.9B of outstanding debt) which currently stands at ~5x debt/ebitda which provides the Co. little margin for error going forward, and 3) the potential for generic entry on Copaxone 40mg in 2017 – Copaxone remains a key contributor to the Co.’s sales (19% of total), and operating profits (42% of total). While Copaxone 40mg is protected by five Orange Book listed patents, we think a key US District (Delaware) Court decision is upcoming in early 2017. While the shares were down ~8% today, we think the near term risks outweigh any potential upside that might occur with this upcoming legal decision," said the analyst.
Shares of Teva Pharma closed at $37.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Barclays Downgrades Lexington Realty Trust (LXP) to Underweight
- Morgan Stanley Downgrades Workiva (WK) to Equalweight, Says Owning The Stock Could be Challenging In 2017
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!